F.D.A. Rejects Closely Watched Lung Cancer Drug From China
The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.
This is a brief. The reporting belongs to NYT Business — read the complete story, with full context and credits, at the source.
Read the full story at NYT Business ↗nytimes.com
How other newsrooms are covering it
More from the Business desk
Treasury Secretary Scott Bessent says if Nvidia was a bank, ‘a lot of the executives would be removed’ — while Huang reportedly eyes return
Megaspeed Says Alice Huang Left Company in August 2025
Transportation secretary still doesn’t totally rule out that a cyberattack may have hit the FAA, and the FBI is assisting the probe
The Guardian view on Cop31: the green transition must not be derailed | Editorial
